Charles Prince - Johnson Johnson Independent Director

<div class='circular--portrait' style='background:#FF6600;color: white;font-size:3em;padding-top: 35px;;'>JNJ</div>
JNJ -- USA Stock  

Earnings Report: April 21, 2020  

Mr. Charles O. Prince, III. J.D, is an Independent Director of the Company. Mr. Prince served as Chief Executive Officer of Citigroup Inc. from 2003 to 2007 and as Chairman from 2006 to 2007. Previously he served as Chairman and Chief Executive Officer of Citigroups Global Corporationrationrate and Investment Bank from 2002 to 2003 and Chief Operating Officer from 2001 to 2002, and held positions of increasing responsibility since joining Commercial Credit Company, a predecessor to Citigroup, in 1979. Mr. Prince began his career as an attorney at U.S. Steel Corporationrationration in 1975. Mr. Prince is a member of the Council on Foreign Relations and The Council of Chief Executives.
Age: 68  Director Since 2006      
732 214-0332

Charles Prince Latest Insider Activity

Charles Prince over three months ago via Macroaxis 
Johnson Johnson exotic insider transaction detected

Management Efficiency

The company has Return on Asset of 0.01 % which means that on every $100 spent on asset it made $0.01 of profit. This is way below average. In the same way, it shows return on shareholders equity (ROE) of 0.02 % implying that it generated $0.02 on every 100 dollars invested.
The company has 30.43 B in debt with debt to equity (D/E) ratio of 50.0 . This implies that the company may be unable to create cash to meet all of its financial commitments. Johnson Johnson has Current Ratio of 1.3 demonstrating that it may not be capable to disburse its financial commitments when the payables are due.

Similar Executives

Showing few of many executives


Stephanie BurnsGlaxoSmithKline PLC
Michael GallagherAllergan Plc
Lynn ElsenhansGlaxoSmithKline PLC
Wendell WeeksMerck Company
JeanPhilippe CourtoisAstrazeneca PLC
Shriti VaderaAstrazeneca PLC
Michael GrobsteinBristol Myers Squibb Company
Daniel PodolskyGlaxoSmithKline PLC
John CoganGilead Sciences
Deborah DiSanzoAstrazeneca PLC
Marcus WallenbergAstrazeneca PLC
Bruce BurlingtonAstrazeneca PLC
Ellen MarramEli Lilly And Company
Judy LewentGlaxoSmithKline PLC
Thomas GlocerMerck Company
Jacqueline BartonGilead Sciences
Vindi BangaGlaxoSmithKline PLC
Nesli BasgozAllergan Plc
Kevin LoftonGilead Sciences
Pamela CraigMerck Company
Harish ManwaniGilead Sciences

Entity Summary

Johnson Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. The company was incorporated in 1887 and is based in New Brunswick, New Jersey. Johnson Johnson operates under Drug ManufacturersGeneral classification in USA and is traded on BATS Exchange. It employs 135100 people.Johnson Johnson (JNJ) is traded on BATS Exchange in USA. It is located in One Johnson and Johnson Plaza, New Brunswick, NJ 08933, United States and employs 135,100 people. Johnson Johnson is listed under Pharmaceutical Products category by Fama And French industry classification.

Johnson Johnson Leadership Team

A Washington, Independent Director
Jennifer Doudna, Independent Director
Alex Gorsky, Chairman, CEO, Chairman of Executive Committee and Chairman of Fin. Committee
William Perez, Independent Director
Michael Sneed, Executive Vice President - Global Corporate Affairs and Chief Communication Officer
Marillyn Hewson, Independent Director
Jorge Mesquita, Executive Vice President Worldwide Chairman - Consumer
Mary Coleman, Independent Director
Michael Ullmann, VP, General Counsel and Member of Executive Committee
Joaquin Duato, Executive Vice President Worldwide Chairman - Pharmaceuticals
Kathy Wengel, Executive Vice President Chief Global Supply Chain Officer
Jennifer Taubert, Executive Vice President - Worldwide Chairman, Pharmaceuticals
Mary Beckerle, Independent Director
Sandra Peterson, Group Worldwide Chairman and Member of Executive Committee
Scott Davis, Director
Louise Mehrotra, Vice President Investor Relations
Ashley McEvoy, Executive Vice President - Worldwide Chairman, Medical Devices
Ronald Williams, Independent Director
Kathryn Wengel, Executive Vice President Chief Global Supply Chain Officer
D Davis, Independent Director
Hubert Joly, Director
Anne Mulcahy, Lead Independent Director
Joseph Wolk, Chief Financial Officer, Executive Vice President
Thibaut Mongon, Executive Vice President Worldwide Chairman, Consumer
Ian Davis, Independent Director
Paulus Stoffels, Worldwide Chairman of Pharmaceuticals, Chief Scientific Officer and Member of Executive Committee
Mark McClellan, Independent Director
Charles Prince, Independent Director
Eugene Washington, Independent Director
Dominic Caruso, CFO, VP of Fin. and Member of Executive Committee
Peter Fasolo, Chief Human Resource Officer, Executive Vice President
Susan Lindquist, Independent Director
Mark Weinberger, Director

Stock Performance Indicators

Current Sentiment - JNJ

Johnson Johnson Investor Sentiment

Predominant part of Macroaxis users are currently bullish on Johnson Johnson. What is your judgment towards investing in Johnson Johnson? Are you bullish or bearish?
98% Bullish
2% Bearish

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please also see Risk vs Return Analysis. Please also try Pair Correlation module to compare performance and examine historical correlation between any two equity instruments.